D. Lacey

Molecular Biology · 2000–2012

A researcher in the Science corpus: 12 papers; trusts 2 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 61 citations into it; #13,824 of 17,773 by trust here, #3,533 by citations
• Oncology — 39 citations into it; #1,199 of 1,698 by trust here, #416 by citations
• Orthopedics and Sports Medicine — 12 citations into it

Whom D. Lacey trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. S. Khosla
2. S. Teitelbaum

Who trusts D. Lacey overall

1. S. Khosla

Papers from D. Lacey's perspective

Ordered by how strongly the researchers D. Lacey trusts endorse each paper. Same corpus, a different order for every researcher.

1. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. (Endocrine reviews)
2. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. (Journal of Clinical Investigation)
3. Therapeutic approaches to bone diseases. (Science)
4. The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption (Journal of Bone and Mineral Research)
5. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ (Nature)
6. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β (Nature)
7. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. (Experimental Cell Research)
8. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. (Developmental Cell)
9. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. (American Journal of Pathology)
10. Bone resorption by osteoclasts. (Science)

Their papers

• Osteoclast differentiation and activation (2003) — 6,592 citations
• The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. (2000) — 776 citations
• The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption (2000) — 1,205 citations
• Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. (2010) — 911 citations
• Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. (2003) — 804 citations
• Dickkopf-1 is a master regulator of joint remodeling (2007) — 1,345 citations
• Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis (2009) — 773 citations
• Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis (2000) — 599 citations
• Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab (2012) — 645 citations
• Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength (2008) — 956 citations
• Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. (2000) — 634 citations
• RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. (2000) — 1,176 citations